



December 2, 2020

Dear Angelman Community,

As you have most likely already heard, yesterday we announced topline results from our Phase 3 NEPTUNE trial for the treatment of Angelman syndrome. OV101 (gaboxadol) did not meet its primary endpoint. This result is deeply disappointing and unexpected.

Despite yesterday's results, I am encouraged by the fact that, together with the Angelman community, Ovid set out to transform the lives of those with Angelman syndrome and their families. In doing so, we hope to have paved the way for others to develop potential treatments and we support that mission. We are encouraged by the number of companies and others who have entered the field. There is real hope for the future.

Regarding OV101: in the coming days, weeks, and months, we will evaluate the data from the trial so we can learn and understand what led to this result. In addition, we plan to continue with the ELARA open label study and report those interim results in the first quarter of 2021.

Additionally we plan to progress our early mRNA and shRNA programs (OV881/OV882) and look forward to providing future updates on these early development programs in Angelman syndrome.

I join all of Ovid in thanking you for continued support and collaboration. We are steadfast in supporting the shared mission to bring potential therapies to individuals and families affected by Angelman syndrome.

Please don't hesitate to reach out if you would like to discuss more. I wish you, your families and the entire Angelman community my very best as we enter the holiday season and new year.

All the best,  
Jeremy Levin

A handwritten signature in blue ink that reads "Jeremy Levin". The signature is written in a cursive, flowing style.